Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 19.91
(1.01%)
CNY 19.91
(1.01%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 583.04 Million CNY | 2319.23% |
| 2022 | 24.1 Million CNY | 911.08% |
| 2021 | 2.38 Million CNY | 1157.47% |
| 2020 | -225.41 Thousand CNY | -102.25% |
| 2019 | 10 Million CNY | 0.0% |
| 2018 | - CNY | -100.0% |
| 2017 | 3.23 Million CNY | -67.66% |
| 2016 | 10 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 649.58 Million CNY | 11.57% |
| 2024 Q3 | 670.55 Million CNY | 0.81% |
| 2024 Q2 | 665.16 Million CNY | 3.42% |
| 2023 Q3 | 608.71 Million CNY | 587.18% |
| 2023 Q2 | 88.58 Million CNY | 115.39% |
| 2023 Q1 | 41.12 Million CNY | 70.64% |
| 2023 FY | 583.04 Million CNY | 2319.23% |
| 2023 Q4 | 583.04 Million CNY | -4.22% |
| 2022 Q4 | 24.1 Million CNY | 210.27% |
| 2022 Q3 | 7.76 Million CNY | 173.28% |
| 2022 Q2 | 2.84 Million CNY | -4.53% |
| 2022 FY | 24.1 Million CNY | 911.08% |
| 2022 Q1 | 2.97 Million CNY | 24.9% |
| 2021 Q4 | 2.38 Million CNY | 0.0% |
| 2021 Q3 | - CNY | 0.0% |
| 2021 Q2 | - CNY | 0.0% |
| 2021 FY | 2.38 Million CNY | 1157.47% |
| 2021 Q1 | - CNY | 100.0% |
| 2020 FY | -225.41 Thousand CNY | -102.25% |
| 2020 Q4 | -225.41 Thousand CNY | -100.54% |
| 2020 Q3 | 41.56 Million CNY | 315.0% |
| 2020 Q2 | 10.01 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 FY | 10 Million CNY | 0.0% |
| 2019 Q4 | 10 Million CNY | 0.0% |
| 2018 FY | - CNY | -100.0% |
| 2017 FY | 3.23 Million CNY | -67.66% |
| 2016 FY | 10 Million CNY | 0.0% |